Sigrid Balser

418 total citations
15 papers, 303 citations indexed

About

Sigrid Balser is a scholar working on Immunology, Pediatrics, Perinatology and Child Health and Oncology. According to data from OpenAlex, Sigrid Balser has authored 15 papers receiving a total of 303 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Immunology, 5 papers in Pediatrics, Perinatology and Child Health and 5 papers in Oncology. Recurrent topics in Sigrid Balser's work include Biosimilars and Bioanalytical Methods (7 papers), Pharmaceutical studies and practices (4 papers) and Neutropenia and Cancer Infections (3 papers). Sigrid Balser is often cited by papers focused on Biosimilars and Bioanalytical Methods (7 papers), Pharmaceutical studies and practices (4 papers) and Neutropenia and Cancer Infections (3 papers). Sigrid Balser collaborates with scholars based in United States, Germany and Switzerland. Sigrid Balser's co-authors include Philip J. Lowe, Wojciech Krzyżański, Uwe Fuhr, Etienne Pigeolet, M. Kinzig‐Schippers, А. Н. Махсон, Suzanne Einmahl, Pere Gascón, Michael Muenzberg and Martin Fink and has published in prestigious journals such as Annals of Oncology, Journal of the American Academy of Dermatology and Clinical Pharmacology & Therapeutics.

In The Last Decade

Sigrid Balser

14 papers receiving 291 citations

Peers

Countries citing papers authored by Sigrid Balser

Since Specialization

Citations

This map shows the geographic impact of Sigrid Balser's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sigrid Balser with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sigrid Balser more than expected).

Fields of papers citing papers by Sigrid Balser

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sigrid Balser. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sigrid Balser. The network helps show where Sigrid Balser may publish in the future.

Co-authorship network of co-authors of Sigrid Balser

This figure shows the co-authorship network connecting the top 25 collaborators of Sigrid Balser. A scholar is included among the top collaborators of Sigrid Balser based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sigrid Balser. Sigrid Balser is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	A Randomised, Double-Blind Trial to Compare the Efficacy, Safety, and Immunogenicity of the Biosimilar Ustekinumab FYB202 with Reference Ustekinumab in Patients with Moderate-to-Severe Plaque Psoriasis 2025 ·Advances in Therapy ·Kim Papp, Sigrid Balser, (unknown), (unknown), (unknown), (unknown)	0
2	New Ustekinumab Biosimilar Candidate FYB202: Pharmacokinetic Equivalence Demonstrated in a Randomized, Double‐Blind, Parallel‐Group, Single‐Dose Trial in Healthy Subjects 2024 ·Clinical Pharmacology in Drug Development ·Sigrid Balser, (unknown), (unknown), Ralph‐Steven Wedemeyer, (unknown), Barbara Schug	2
3	Phase 3 Trial of BI 695502 Plus Chemotherapy Versus Bevacizumab Reference Product Plus Chemotherapy in Patients With Advanced Nonsquamous NSCLC 2021 ·JTO Clinical and Research Reports ·Edward S. Kim, Sigrid Balser, Klaus Röhr, (unknown), Bernd Liedert, Dorothee E. Schliephake	5
4	Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial 2021 ·The Lancet. Gastroenterology & hepatology ·Stephen B. Hanauer, Bernd Liedert, Sigrid Balser, (unknown), Viktoria Moschetti, Stefan Schreiber	30
5	13097 Biosimilar BI 695501 demonstrates clinical equivalence to adalimumab reference product in patients with moderate to severe chronic plaque psoriasis through 24 weeks 2020 ·Journal of the American Academy of Dermatology ·Alan Menter, Petr Arenberger, Sigrid Balser, Stefan Beissert	4
6	Similar efficacy, safety, and immunogenicity of the biosimilar BI 695501 and adalimumab reference product in patients with moderate-to-severe chronic plaque psoriasis: results from the randomized Phase III VOLTAIRE-PSO study 2020 ·Expert Opinion on Biological Therapy ·Alan Menter, Petr Arenberger, Sigrid Balser, Stefan Beissert, (unknown), Niklas Czeloth, Jennifer Soung, S. Jazayeri, Peter Weisenseel, (unknown)	18
7	Population Pharmacokinetic and Pharmacodynamic Model‐Based Comparability Assessment of a Recombinant Human Epoetin Alfa and the Biosimilar HX575 2011 ·The Journal of Clinical Pharmacology ·Xiaoyu Yan, Philip J. Lowe, Martin Fink, (unknown), Sigrid Balser, Wojciech Krzyżański	31
8	Long-term safety and efficacy of the recombinant human growth hormone omnitrope® in the treatment of Spanish growth hormone deficient children: Results of a phase III study 2011 ·Advances in Therapy ·Juan Pedro López‐Siguero, (unknown), Sigrid Balser, (unknown)	23
9	Effect of switching recombinant human growth hormone: Comparative analysis of phase 3 clinical data 2011 ·PubMed ·T E Romer, (unknown), Mieczysław Walczak, Mieczysław Szalecki, Sigrid Balser	14
10	Pharmacokinetic Similarity of Biologics: Analysis Using Nonlinear Mixed-Effects Modeling 2011 ·Clinical Pharmacology & Therapeutics ·Anne Dubois, Sandro Gsteiger, Sigrid Balser, Etienne Pigeolet, Jean‐Louis Steimer, Goonaseelan Pillai, France Mentré	17
11	Bioequivalence between novel ready-to-use liquid formulations of the recombinant human GH Omnitrope and the original lyophilized formulations for reconstitution of Omnitrope and Genotropin 2010 ·European Journal of Endocrinology ·Uwe Fuhr, (unknown), (unknown), Sigrid Balser, (unknown), Paul Saenger	17
12	Population Modeling of Filgrastim PK‐PD in Healthy Adults Following Intravenous and Subcutaneous Administrations 2010 ·The Journal of Clinical Pharmacology ·Wojciech Krzyżański, Paweł Wiczling, Philip J. Lowe, Etienne Pigeolet, Martin Fink, (unknown), Sigrid Balser	36
13	Population Pharmacokinetic Modelling of Filgrastim in Healthy Adults following Intravenous and Subcutaneous Administrations 2009 ·Clinical Pharmacokinetics ·Paweł Wiczling, Philip J. Lowe, Etienne Pigeolet, Frank Lüdicke, Sigrid Balser, Wojciech Krzyżański	20
14	Development of a new G-CSF product based on biosimilarity assessment 2009 ·Annals of Oncology ·Pere Gascón, Uwe Fuhr, F. Sörgel, M. Kinzig‐Schippers, А. Н. Махсон, Sigrid Balser, Suzanne Einmahl, Michael Muenzberg	77
15	Establishment and validation of an ex vivo human cervical tissue model for local delivery studies 2007 ·European Journal of Pharmaceutics and Biopharmaceutics ·Christian Hiller, Udo Bock, Sigrid Balser, Eleonore Haltner‐Ukomadu, Michael Dahm	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact